The company will evaluate around 20 patients with type 1 diabetes in the Phase IIa trial.
The results from a Phase I trial demonstrated that the action of HinsBet is as fast as that of NovoLog and has less variability.
Adocia president and CEO Gerard Soula said they expect the study to confirm HinsBet’s similar efficacy on type 1 diabetics compared with Novo Nordisk’s fast-acting insulin analog.